Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (5) , 839-846
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
- AbbVie
- Gilead Sciences
This publication has 38 references indexed in Scilit:
- Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal functionLiver International, 2016
- Hepatitis C virus infection in Taiwan: Past, present, and futureJournal of the Formosan Medical Association, 2016
- Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal InjuryAmerican Journal of Gastroenterology, 2016
- Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus GenotypingJournal of Clinical Microbiology, 2015
- Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis CDrugs, 2014
- Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective StudyThe Journal of Infectious Diseases, 2012
- Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort StudyJournal of Clinical Oncology, 2010
- Mesangial Matrix Modulation and GlomerulosclerosisNephron Experimental Nephrology, 1999
- Overview: Renal Physiology and Pathophysiology of AgingAmerican Journal of Kidney Diseases, 1990
- Effects of aging on the renal glomerulusThe American Journal of Medicine, 1986